Serum 25-hydroxyvitamin D and subsequent cancer incidence and mortality: A population-based retrospective cohort study
Mayo Clinic Proceedings Aug 08, 2021
Johnson CR, Dudenkov DV, Mara KC, et al. - Elevated risk for incident nonskin cancer and cancer-related mortality was present in relation to low 25-hydroxyvitamin D (25[OH]D) levels.
Of 8,700 persons without cancer history and with mean ± SD age of 51.5±16.4 years, 761 suffered from cancer during follow-up.
Post-adjustment, a greater nonskin cancer incidence was noted in relation to 25(OH)D values less than 12 ng/mL, vs 25(OH)D values of 20 to 50 ng/mL (reference group).
Increased cancer mortality was associated with 25(OH)D levels less than 12 ng/mL and 12 to 19 ng/mL, vs the reference group.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
